Trial intelligence / Profile preview

Paclitaxel, Carboplatin + Bevacizumab in Pretreated Advanced NSCLC

NCT00753909Phase 2

Key facts

Status: Completed
Start: Nov 2008
Primary completion: Oct 2016
Countries: 1
Sponsor: Hellenic Oncology Research Group
Modality: Monoclonal Antibodies

Drugs: bevacizumab
Conditions: non-small cell lung cancer (NSCLC)

Overview

Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Hellenic Oncology Research Group. Primary endpoint: Overall Response Rate. Started Nov 2008; status: completed.

Design

1 arm

Study design: Non-randomizedOpen-labelSingle group

Paclitaxel/Carboplatin/Bevacizumab
Paclitaxel (IV) 140 mg/m2 + Carboplatin (IV) AUC 3 + Bevacizumab (IV) 10 mg/kg on day 1 and 15 every 4 weeks for 6 cycles, followed by Bevacizumab maintenance.

Endpoints

Primary

Overall Response Rate6th cycle

Secondary

Toxicity profileEach chemotherapy cycle
Time to Tumor Progression1 year
Overall Survival1 year

Beyond the preview

Go deeper on NCT00753909.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00753909.